Compared with HBV–HCC patients, NBNC–HCC patients may exhibit a weaker response to PD-1 inhibitors, suggesting that clinicians can screen HCC subgroups suitable for immunotherapy on the basis of etiology to obtain improved efficacy. Here, PDCD1 is linked to hepatocellular carcinoma.